ClinicalTrials.gg
RecruitingNCT06349083Updated Sep 2, 2026

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

A Phase 2 interventional study of Psilocybin and Inactive Placebo in Alcohol Use Disorder, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by NYU Langone Health · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing psilocybin in Alcoholism — 8 open to participants now, 13 under way, 1 of them phase 3. Psilocybin · Alcoholism.

Planned enrollment
Largest of 17
200 · median 62
Started
2026
with 3 others
Phase 2
16 of 17
7 open now
Primary completion
2030-05
later than 11 of 12 live
Registered
11th of 17
by date
Lead sponsor
2 of 17
NYU Langone Health

Among the 17 studies testing psilocybin in Alcoholism, this one has the largest planned enrollment, is one of 4 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 11 of the 12 other live ones, and was the 11th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

8 of the 17 studies testing psilocybin in Alcoholism are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing psilocybin in Alcoholism, or all of them as a file.
02

Study summary

This is a double-blind, randomized, placebo-controlled Phase 2 mechanistic clinical trial designed to evaluate the therapeutic neural mechanisms of psilocybin in patients with alcohol use disorder (AUD), and to determine whether further studies are warranted to study the relationship of any such effects to clinical improvement in AUD symptoms. The primary aims are to evaluate the effects of psilocybin on AUD; measures will include 1) fMRI neural activation and functional connectivity, using a well-validated task to characterize neural and subjective response to negative affective and alcohol visual stimuli; 2) alcohol use data (self-report and blood biomarkers); and 3) self-report measures related the NE, IS, and EF domains.

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

Keywords

  • psilocybin
  • AUD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are able to provide voluntary
  2. Have a breath alcohol concentration (BrAC) ≤ 0.01% at screening, as determined by a breath alcohol reading from a calibrated breath alcohol sensor. (Note: this criterion may be re-evaluated within the 30-day screening period.
  3. Are able to read, speak, and understand English, as documented during the informed consent process.

    a. Non-English speaking subjects will be excluded because the study is using only validated English-language versions of assessment instruments.

  4. Are 18 to 65 years old, inclusive, at Screening visit.
  5. Have diagnosis of moderate or severe AUD (using MINI)
  6. Eligible participants must either (a) not currently receiving treatment for alcohol use disorder (AUD), or (b) have been in continuous treatment for AUD for at least 3 months and plan to continue. (Any medications used to treat AUD would need to be discontinued no less than 5 half lives or 14 days (whichever is greater) prior to the IP administration session. Patients who who are completing detoxification from alcohol and do not have plans for follow-up treatment would be eligible to participate in the study after completion of the detoxification program).
  7. Are able and willing to adhere to all study requirements, including attending all study visits and therapy sessions, and completing all assessments.
  8. Have least 4 heavy drinking days (4 or more drinks per day for a woman, 5 or more drinks per day for a man) in the 30 days prior to admission to the screening visit.
  9. Agree to refrain from alcohol use as well as any non-prescribed psychotropic substance or illicit drug use for at least 24 hours prior to product (IP) administration and before each fMRI assessment visit, with the exceptions of nicotine and caffeine. Regarding nicotine, they must agree not to use nicotine for at least 1 hour before and 6 hours following IP administration, and for at least 1 hour before fMRI scans. Regarding caffeine, they must agree to consume approximately their usual amount of caffeine on the morning of Day 0 (prior to IP administration).
  10. Agree to refrain from taking all non-prescription medications and supplements (nutritional and herbal) for at least 1 week prior to the IP administration session unless approved by the Investigator.
  11. Are able to swallow capsules.
  12. If able to become pregnant, have a negative serum pregnancy test at screening.
  13. If able to become pregnant or produce viable sperm (male or female), are willing to use approved for duration of the trial
  14. Able to provide at least 2 locators.
  15. Participants must be able to commit to being sober at the time all treatment sessions and the two fMRI sessions, and to stay sober from the time of the drug administration until the second fMRI session.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Any medical condition that would preclude safe participation in the study, including the following, as determined by medical history review, physical examination, (ECG), and clinical laboratory tests:

    1. Seizure disorder
    2. Significantly impaired liver function, defined as 1) (ALT) and/or aspartate aminotransferase (AST) > 5 × (ULN); 2) ALT or AST > 3 × ULN with concomitant total > 2.0 × ULN; or 3) ALT or AST ≥ 3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia.
    3. Cardiovascular disease including coronary artery disease, angina, history of arrhythmia (unless a successful ablation has been performed), heart failure, history of heart valve replacement, and history of cerebrovascular accident or .
    4. Uncontrolled hypertension with systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg. (Note: participants who otherwise meet all eligibility criteria during the screening visit will have 3 opportunities to produce 1 blood pressure reading ≤ 140/90 mmHg (each reading will be collected at least 15 minutes apart). If blood pressure at Screening is consistently elevated (> 140/90 mmHg across all 3 attempts), participants may be referred to their medical provider for management of hypertension. Participants may continue study participation if they are able to provide documentation of adequate control (BP > 140/90 mmHg) prior to the IP administration session.)
    5. Resting heart rate > 100 bpm (Note: participants will have an opportunity to return once within the 30 day screening window to make 3 additional attempts at a resting heart rate ≤ 100 bpm.).
    6. Serious ECG abnormalities present on the ECG obtained at the screening visit (e.g., evidence of ischemia, myocardial infarction, corrected for heart rate [QTc] prolongation (QTc > 0.450 seconds), arrhythmia, or conduction abnormalities that increase the risk of arrhythmia.
    7. Hyperthyroidism
    8. Insulin-dependent diabetes
    9. Any other medical condition which precludes safe participation in the study in the medical opinion of the Investigator. (Note: medical history will be updated on Day 0. Those not meeting the criterion will not be randomized but may be rescheduled once within 14 days if the criterion is likely to resolve within 14 days in the judgement of the Investigator.)
  3. Have any of the following psychiatric disorders, as determined by the MINI and Psychiatric History at the Screening Visit: (Note: psychiatric history will be re-evaluated on Day 0, but the MINI will not be re-administered on Day 0)

    1. Lifetime history of schizophrenia spectrum or other psychotic disorder (including substance or medication-induced psychosis or psychosis due to a co-occurring medical condition).
    2. Current alcohol withdrawal (CIWA-Ar score >7)
    3. History of mania
  4. Have active suicidal ideation with intent, based on Columbia-Suicide Severity Rating Scale (C-SSRS) (past week severity score >3) at the Screening visit, confirmed by the Investigator. (Note: this criterion will be reassessed at each visit that occurs prior to Day 0, and on Day 0 prior to randomization. Participants will be withdrawn if actively suicidal, and appropriate follow-up will be arranged.
  5. Have made a medically significant suicide attempt (i.e., one that had a significant possibility of causing death or permanent harm in the absence of intervention) within the past 12 months, based on Screening C-SSRS assessment and confirmation by the Investigator. (Note: this criterion will be reassessed at each visit that occurs prior to Day 0, and on Day 0 prior to randomization. Participants will be withdrawn if actively suicidal, and appropriate follow-up will be arranged.)
  6. Have a family history (first degree relatives) of schizophrenia, schizoaffective disorder, or bipolar disorder type 1.
  7. Have a history of hallucinogen use disorder.
  8. Have a history of hallucinogen persisting perceptual disorder (HPPD).
  9. Have any use of classic psychedelics in the past 1 year.
  10. Have > 25 lifetime uses of classic psychedelics.
  11. Incarcerated or have pending legal action that could prevent participation in study activities.
  12. Are court-mandated to complete treatment or are a prisoner.
  13. Are unable or unwilling to discontinue taking any protocol-prohibited medications and supplements. (A detailed list of exclusionary medications is found in Section 6.5 of the protocol). Current SSRI use is allowed only if the dose has been stable for at least one month at the time of Screening visit. Prohibited medications and supplements must have been stopped for at least 5 elimination half-lives or 14 days, whichever is longer, prior to Day 0 (Note: Psychiatric medications will not be discontinued or changed in order to allow study participation unless such change does not cause any increase in risk to the study participant, in the judgement of the study physician and the prescribing provider. For example, a change in a medication for sleep might be appropriate if a non-exclusionary alternative is available. Any such study-related changes in medication will be documented in a progress note which will include explanation for why the change does not increase overall clinical risk and documentation of the prescribers concurrence with the treatment plan.)

    a. Note that any medication prescribed to the participant for AUD is exclusionary, including FDA-approved medications as well those prescribed off-label, such as topiramate, ondansetron, gabapentin, and varenicline.

  14. Have a known allergy or to psilocybin or any of the materials contained in the IP used in the study.
  15. Have an allergy, hypersensitivity, or other that would preclude safe treatment of acute hypertension, anxiety, or psychotic symptoms if necessary during or immediately after the IP Administration Session, using the adjunctive medications used in this study to treat these symptoms (i.e., unable to take captopril and unable to take clonidine; unable to take diazepam; or unable to take olanzapine).
  16. Have any other medical, psychiatric, or psychosocial disorder, symptom, condition, or situation that is likely to interfere with the establishment of rapport, adherence to study requirements, or safe administration of psilocybin or fMRI scanning, based on the judgement of the Investigator.
  17. Inability to safely complete fMRI sessions (MRI screening form), including presence of metallic implants or devices that contraindicate MRI or claustrophobia.
  18. Any history of severe traumatic brain injury (assessed using OSU TBI-ID modified). (Note: If current (past 12 months) mild/moderate TBI and CSI score >/=12 (for either lifetime month or current month), the PI will determine eligibility.)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Oral high-dose of psilocybin

    Participants will receive a single IP administration session of psilocybin (30 mg total) and four supportive therapy sessions.

    Drug: Psilocybin · Behavioral: Supportive therapy sessions

  • Placebo comparator
    Placebo control

    Participants will receive a single IP administration session of matching placebo capsules and four supportive therapy sessions.

    Other: Inactive Placebo · Behavioral: Supportive therapy sessions

Interventions

  • One 25 mg capsule and one 5 mg capsule (30 mg total) administered once orally

  • OtherInactive Placebo

    Two matching placebo capsules administered once orally

  • BehavioralSupportive therapy sessions

    Participants will receive four supportive therapy sessions of manual-based treatment from two Center for Psychedelic Medicine (CPM) clinicians. The lead clinician will be a licensed physician, clinical psychologist, or nurse practitioner who will be primarily responsible for the content of the intervention. The second therapist will have at least a master's degree or be pursuing a master's or doctoral degree in a related clinical field.

06

What researchers measure

Primary outcomes

  1. Percent change in the alcohol cue-induced Blood-oxygen-level dependent (BOLD) signal in the lateral prefrontal cortex (PFC)

    Percentage change in the BOLD signal is the difference in fMRI signal between the baseline condition (B) and the alcohol cue-induced task condition (T); percent signal change = (T-B)/B×100%. A positive value of the percentage change in BOLD signal indicates up-regulation of BOLD signal.

    Time frame: Baseline, Day 2

  2. Percent change in the alcohol cue-induced BOLD signal change in the caudate

    Percentage change in the BOLD signal is the difference in fMRI signal between the baseline condition (B) and the alcohol cue-induced task condition (T); percent signal change = (T-B)/B×100%. A positive value of the percentage change in BOLD signal indicates up-regulation of BOLD signal.

    Time frame: Baseline, Day 2

  3. Percent change in alcohol cue-induced BOLD signal change in the ventromedial PFC (vmPFC)

    Percentage change in the BOLD signal is the difference in fMRI signal between the baseline condition (B) and the alcohol cue-induced task condition (T); percent signal change = (T-B)/B×100%. A positive value of the percentage change in BOLD signal indicates up-regulation of BOLD signal.

    Time frame: Baseline, Day 2

  4. Percent change in alcohol cue-induced BOLD signal change in the inferior frontal gyrus (IFG)

    Percentage change in the BOLD signal is the difference in fMRI signal between the baseline condition (B) and the alcohol cue-induced task condition (T); percent signal change = (T-B)/B×100%. A positive value of the percentage change in BOLD signal indicates up-regulation of BOLD signal.

    Time frame: Baseline, Day 2

  5. Percent change in alcohol cue-induced BOLD signal change in the insula

    Percentage change in the BOLD signal is the difference in fMRI signal between the baseline condition (B) and the alcohol cue-induced task condition (T); percent signal change = (T-B)/B×100%. A positive value of the percentage change in BOLD signal indicates up-regulation of BOLD signal.

    Time frame: Baseline, Day 2

  6. Percent change in negative affective cue-induced BOLD signal change in the dorsomedial PFC (dmPFC)

    Percentage change in the BOLD signal is the difference in fMRI signal between the baseline condition (B) and the alcohol cue-induced task condition (T); percent signal change = (T-B)/B×100%. A positive value of the percentage change in BOLD signal indicates up-regulation of BOLD signal.

    Time frame: Baseline, Day 2

  7. Percent change in negative affective cue-induced BOLD signal change in the supramarginal gyrus

    Percentage change in the BOLD signal is the difference in fMRI signal between the baseline condition (B) and the negative affective cue-induced task condition (T); percent signal change = (T-B)/B×100%. A positive value of the percentage change in BOLD signal indicates up-regulation of BOLD signal.

    Time frame: Baseline, Day 2

  8. Percent change in negative affective cue-induced BOLD signal change in the amygdala

    Percentage change in the BOLD signal is the difference in fMRI signal between the baseline condition (B) and the negative affective cue-induced task condition (T); percent signal change = (T-B)/B×100%. A positive value of the percentage change in BOLD signal indicates up-regulation of BOLD signal.

    Time frame: Baseline, Day 2

  9. Percent change in negative affective cue-induced BOLD signal change in the insula

    Percentage change in the BOLD signal is the difference in fMRI signal between the baseline condition (B) and the negative affective cue-induced task condition (T); percent signal change = (T-B)/B×100%. A positive value of the percentage change in BOLD signal indicates up-regulation of BOLD signal.

    Time frame: Baseline, Day 2

  10. Percent change in alcohol cue-induced functional connectivity in prespecified regions of interest (ROI)

    ROI include the ventral striatum, lateral PFC (dlPFC and IFG), and caudate with target clusters in the PFC, ACC, and sensorimotor cortex (S1 and M1).

    Time frame: Baseline, Day 2

  11. Percent change in negative affective cue-induced functional connectivity in prespecified regions of interest (ROI)

    ROI include the ventral striatal and amygdala with target clusters in temporal and occipital regions relative to placebo.

    Time frame: Baseline, Week 4

  12. Percent change in the frequency of failed response inhibition

    A Go/NoGo task will be used as an objective measure of response inhibition. This task includes alcohol, non-alcohol, and neutral stimuli. The Go/No-go task requires participants to respond by pressing a button when they see a "go" signal, and not respond when they see the "no-go" signal. The key behaviour measured with this experiment is the participants' ability to withhold a response on No-go trials and the frequency of their failed responses.

    Time frame: Baseline, Week 4

  13. Change in discounting rate (log(k))

    The discounting rate is derived from the Delay Discounting Task. Delay discounting tasks provide a measure of the temporal window and examine the devaluation of awards as a function of the delay to the receipt. The task includes 80 items requiring a choice between a delayed reward of $100 and smaller immediate rewards (ranging from $10 to $99, at delays ranging from one to 365 days. Discounting rates will be measured and pre-post differences will be assessed. Higher k values indicate higher impulsive decision-making.

    Time frame: Baseline, Week 4

  14. Change in participant-level reference points

    A Foraging Task will be used as an objective measure of cognitive flexibility. The task involves making "stay" or "go" decisions to harvest apples from stylized "trees" that have hidden initial rewards. Within each block, trees have a mean initial reward rate. Subjects decide to either harvest the tree ("stay") or search for a new one ("go"), incurring an S second delay penalty for searching. Harvesting reveals the reward, which depletes by a fixed amount, plus a small error term. After a 1-second inter-trial interval, the tree reappears for another "stay" or "go" choice. Rewards on each sequential trial are computed. Rewards are computed dynamically, with optimal strategies varying based on the delay penalty. The optimal reference point is calculated using the marginal value theorem, while the empirical reference point is the participant's cutoff for searching.

    Time frame: IP Administration (Day 0), Week 24

  15. Percentage of no heavy drinking days

    Outcome will be measured using the Timeline Followback (TLFB) interview-based assessment. The TLFB derives subjects' retrospective daily estimates of alcohol consumption patterns. Using a calendar as a visual aid, special events, and other memory cues, subjects are guided through the process of recalling and reporting daily drinking estimates.

    Time frame: Baseline, Week 24

  16. Change in phosphatidyl ethanol (PEth) blood levels

    Time frame: Baseline, Week 12

  17. Change in carbohydrate-deficient transferrin (CDT) blood levels

    Time frame: Baseline, Week 12

  18. Change in the Drinker Inventory of Consequences questionnaire (DrInC-2R) total score

    DrInC-2R is a validated self-report questionnaire consisted of 50 questions to measure adverse consequences of alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal as well as frequency of these consequences (answers given on frequency scale grade from 0-3: 0 - never, 1 - once or a few times, 2 - once or twice a week 3 - daily or almost daily). Higher scores indicate greater levels of alcohol-related problems.

    Time frame: Baseline, Week 24

  19. Change in PSQI global score

    Sleep quality is measured by the Pittsburgh Sleep Quality Index (PSQI) . The PSQI is a 19-item, self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations. The 19 items are grouped into 7 components, including (1) sleep duration, (2) sleep disturbance, (3) sleep latency, (4) daytime dysfunction due to sleepiness, (5) sleep efficiency, (6) overall sleep quality, and (7) sleep medication use. Each of the sleep components yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction. Adding up the average scores of the seven factors gives a global PSQI score from 0 to 21, with 0-4 indicating "good" sleep and 5-21 indicating "poor" sleep.

    Time frame: Baseline, Week 24

  20. Change in patient's self-assessed health-related quality of life (by the SF-36 Questionnaire)

    The Short Form Health Survey (SF-36) is a validated 36 item self-report Quality of Life Questionnaire that measures eight multi-item dimensions of health: physical functioning, social functioning, role limitations due to physical problems, role limitations due to emotional problems, mental health, energy/vitality, pain, and general health perception. Scores range from 0 - 100. Lower scores = more disability, higher scores = less disability

    Time frame: Baseline, Week 24

  21. Change in Alcohol craving score

    The alcohol cravings score will be assessed using the Penn Alcohol Craving Scale (PACS). The PACS consists of 5 questions with sub-scales ranging from 0 (never) to 6 (nearly all of the time). Scores greater than 20 were considered to meet diagnostic criteria for craving for a diagnosis of Alcohol Use Disorder.

    Time frame: Baseline, Week 24

  22. Change in negative affect score

    Negative affect will be assessed using the negative affect scale of the Positive and Negative Affect Schedule (PANAS) which is a 10-item measure of negative emotions on a scale of 1 ("very slightly or not at all) to 5 ("extremely"). Total scores can range from 10 - 50, with higher scores representing higher levels of NA and reflect a dimension of general distress summarizing a variety of negative states such as anger, guilt, or anxiety.

    Time frame: Baseline, Week 24

  23. Change in impulsivity score (Barratt impulsivity scale by the subscales and by the total score)

    Impulsivity will be assessed using the Barratt impulsivity scale (BIS-11), a validated self-report questionnaire composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale: Rarely/Never = 1, Occasionally = 2, Often = 3, Almost Always/Always = 4. Total score is assessed. The total scores can range from 30 to 120. The higher total score corresponds to the more impulsive behavior

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Average number of drinks per day

    Outcome will be measured using the Timeline Followback (TLFB) interview-based assessment. The TLFB derives subjects' retrospective daily estimates of alcohol consumption patterns. Using a calendar as a visual aid, special events, and other memory cues, subjects are guided through the process of recalling and reporting daily drinking estimates.

    Time frame: IP Administration (Day 0), Week 24

  2. Percentage of abstinent days

    Outcome will be measured using the Timeline Followback (TLFB) interview-based assessment. The TLFB derives subjects' retrospective daily estimates of alcohol consumption patterns. Using a calendar as a visual aid, special events, and other memory cues, subjects are guided through the process of recalling and reporting daily drinking estimates.

    Time frame: IP Administration (Day 0), Week 24

  3. Time to First Drinking Day

    Outcome will be measured using the Timeline Followback (TLFB) interview-based assessment. The TLFB derives subjects' retrospective daily estimates of alcohol consumption patterns. Using a calendar as a visual aid, special events, and other memory cues, subjects are guided through the process of recalling and reporting daily drinking estimates.

    Time frame: IP Administration (Day 0), Week 24

  4. Time to First Heavy Drinking Day

    Outcome will be measured using the Timeline Followback (TLFB) interview-based assessment. The TLFB derives subjects' retrospective daily estimates of alcohol consumption patterns. Using a calendar as a visual aid, special events, and other memory cues, subjects are guided through the process of recalling and reporting daily drinking estimates.

    Time frame: IP Administration (Day 0), Week 24

  5. Change in World Health Organization (WHO) Risk drinking levels

    Outcome will be measured using the Timeline Followback (TLFB) interview-based assessment. The TLFB derives subjects' retrospective daily estimates of alcohol consumption patterns. Using a calendar as a visual aid, special events, and other memory cues, subjects are guided through the process of recalling and reporting daily drinking estimates. These daily drinking estimates will then be used to categorize participants' risk drinking levels based on WHO criteria, which are based on grams of pure ethanol consumed per day.

    Time frame: Baseline, Week 24

  6. Probability of Having No Drinking Days

    Probability of having no drinking days from the day of IP administration to the Week 24 follow-up will be calculated using a likely responder analysis. Candidate predictors will include fMRI-derived neural metrics (activation and functional connectivity), clinical features, neuropsychological measures, self-report questionnaires, and outcome expectancies. The LR approach uses a prognostic score, a model of the outcome as a function of pre-treatment variables within the treatment group, to predict each participant's potential response under the treatment.

    Time frame: IP Administration (Day 0), Week 24

  7. Probability of Having No Heavy Drinking Days

    Probability of having no heavy drinking days from the day of IP administration to the Week 24 follow-up will be calculated using a likely responder analysis. Candidate predictors will include fMRI-derived neural metrics (activation and functional connectivity), clinical features, neuropsychological measures, self-report questionnaires, and outcome expectancies. The LR approach uses a prognostic score, a model of the outcome as a function of pre-treatment variables within the treatment group, to predict each participant's potential response under the treatment.

    Time frame: IP Administration (Day 0), Week 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon request and approval by the NIH Data Access Committee immediately following article publication or as required by a condition of awards and agreements supporting the research. The NIH will provide access to scientific investigators for research purposes. Investigators requesting shared data must be affiliated with an NIH-recognized research institution (in the NIH's eRA Commons) that maintains an active FWA, and complete and submit a Data Use Certification approved by an authorized institutional business official with signature authority. Once approved, researchers will be granted access to the entire collection of shared data in the NDA research clusters requested. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The NIH will provide access to scientific investigators for research purposes. Investigators requesting shared data must be affiliated with an NIH-recognized research institution (in the NIH's eRA Commons) that maintains an active FWA, and complete and submit a Data Use Certification approved by an authorized institutional business official with signature authority. This request will then be reviewed by the Data Access Committee (DAC). Once approved, researchers will be granted access to the entire collection of shared data in the NDA research clusters requested.

Data sharing details ↗ · nda.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for May 2030, 44 months later.

Of 122 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 44 months is above that.

Counting every sponsor, half of 134 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2024
First posted
Apr 5, 2024
StartEst.
Sep 1, 2026
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06349083
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Apr 5, 2024
Start date
Sep 1, 2026 (estimated)
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Sep 2, 2026

Study contacts

Michael Bogenschutz, MD
Contact
Michael.bogenschutz@nyulangone.org
646-501-4026
Quincey Pyatt
Contact
quincey.pyatt@nyulangone.org
631-386-3455
Michael Bogenschutz, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion